High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia |
| |
Authors: | Hon Y. Chan Frederick J. Meyers Jerry P. Lewis |
| |
Affiliation: | (1) Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis Medical Center, 4301 X Street, 95817 Sacramento, CA, USA |
| |
Abstract: | Summary In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.Abbreviations ANLL acute nonlymphocytic leukemia - CGL chronic granulocytic leukemia - DNR daunorubicin - VNC vincristine - ID Ara-C, intermediate-dose Ara-C (500 mg/m2 for 12 doses) - HD Ara-C, high-dose Ara-C (3 g/m2 for 12 doses) - SGGT serum glutamic transaminase - LDH lactic dehydrogenase - SGOT serum glutamic oxaloacetic transaminase |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|